Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Rhea-AI Summary

Jyong Biotech (Nasdaq: MENS) announced a non-binding letter of intent (LOI) with a South Korean pharmaceutical company to evaluate in-licensing and development of its plant-derived investigational drug MCS-2 for the Korean market.

The prospective partner supplies general hospitals and clinics; the LOI is non-exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and closing conditions. The collaboration would pursue co-commercialization using the partner’s local sales network to accelerate market access if definitive terms are agreed. MCS-2 remains an investigational candidate and is not approved in any jurisdiction. Jyong Biotech said it will provide material updates as developments occur.

News Market Reaction – MENS

+15.16%

16 alerts

+15.16% News Effect

+17.2% Peak Tracked

-10.1% Trough Tracked

+$389M Valuation Impact

$2.96B Market Cap

0.6x Rel. Volume

On the day this news was published, MENS gained 15.16%, reflecting a significant positive market reaction. Argus tracked a peak move of +17.2% during that session. Argus tracked a trough of -10.1% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $389M to the company's valuation, bringing the market cap to $2.96B at that time.

Data tracked by StockTitan Argus on the day of publication.

New Taipei City, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that the Company has entered into a non‑binding letter of intent (the “LOI”) with a South Korean pharmaceutical company to review and evaluate the potential in‑licensing and development of Jyong Biotech’s plant-derived new drug MCS-2for the Korean market. The prospective partner is a recognized supplier to both general hospitals and clinics, and the LOI reflects mutual interest in assessing commercial and regulatory pathways for introducing MCS products in Korea.

This engagement is consistent with Jyong Biotech’s co‑commercialization strategy to collaborate with regional partners that offer established sales networks and local regulatory expertise. Definitive terms are being negotiated between the parties and the partnership, if such definitive terms will be agreed upon, would aim to leverage the partner’s commercial infrastructure to accelerate market access and patient reach in Korea. The LOI is non‑exclusive and subject to customary due diligence, regulatory review, negotiation of definitive agreements, and other closing conditions.

Fu Feng Kuo, Chairwoman of Jyong Biotech, commented: “A selective co‑commercialization approach with strategic partners will enable broader and faster patient access by combining its product development capabilities with partners’ commercial scale and local market knowledge. The Company will work to advance LOI negotiation with these strategic partners and provide updates as material developments occur.”

As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Jyong Biotech Ltd.
ir@jyongbio.com

Investor Relations
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214

FAQ

What did Jyong Biotech (MENS) announce on November 24, 2025 regarding MCS-2 in Korea?

Jyong Biotech announced a non-binding LOI with a South Korean pharmaceutical company to evaluate in-licensing and development of MCS-2 for the Korean market.

Is the LOI between Jyong Biotech (MENS) and the Korean partner exclusive?

No. The LOI is stated to be non-exclusive and subject to due diligence and negotiation of definitive agreements.

What are the next steps after the LOI for Jyong Biotech (MENS) and the prospective Korean partner?

Next steps include due diligence, regulatory review, negotiation of definitive agreements, and satisfaction of closing conditions before any partnership is final.

Does the LOI mean MCS-2 is approved for use in Korea or elsewhere?

No. The company says MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.

How would a definitive agreement with the Korean partner affect Jyong Biotech (MENS) commercialization plans?

A definitive agreement would aim to use the partner’s established sales network and local regulatory expertise to accelerate market access and patient reach in Korea.